10x Genomics vs Singular Genomics
10x Genomics holds the stronger position because it controls about 95% of the spatial genomics market that Singular Genomics is still trying to break into.
10x Genomics
Makes single-cell and spatial genomics instruments and consumables used in biology labs worldwide
Singular Genomics
Spatial biology and sequencing instrument maker, now a small private Deerfield-owned subsidiary
Dimension by dimension
| Dimension | 10x Genomics | Singular Genomics |
|---|---|---|
| staying power of the core product | Generates close to $600 million in yearly revenue with guidance for continued growth into 2026 | Generates just over $1 million in quarterly revenue and was taken private below its IPO price, showing weak commercial traction |
| exposure to AI | AI is unlikely to absorb its single-cell and spatial genomics business | AI is unlikely to absorb its sequencing instrument business |
| how easily a giant copies them | Rated only possible to be copied, reflecting a firmer hold on its market | Rated likely to be copied by a larger player, leaving little to defend its position |
| pressure from rivals | No named rival is confirmed taking share; pressure instead comes from customers delaying purchases before its own new product launch | Faces a market already dominated by 10x Genomics plus Illumina now entering spatial transcriptomics |
| financial footing | Reported $598.7 million in FY2025 revenue and guides for $600 to $625 million in FY2026 | Reported about $1.08 million in Q4 2023 revenue and was bought out at $20.00 per share, below its $22 IPO price |
| overall market standing | Described as defensible for now, reflecting its larger scale despite near term buying delays | Described as protection under test, reflecting its small scale and dependence on a private owner |
Questions people ask
- Which company has a stronger market position, Singular Genomics or 10x Genomics?
- 10x Genomics holds around 95% of the spatial genomics market, while Singular Genomics is a much smaller company still trying to gain a foothold in that same space.
- Is 10x Genomics losing customers to Singular Genomics?
- No named rival is confirmed taking share from 10x Genomics. The pressure it faces right now comes from customers delaying purchases ahead of its own new product launch, not from Singular Genomics.
- Why did Singular Genomics go private?
- Singular Genomics was acquired by Deerfield in a take-private deal at $20.00 per share, below the $22 per share it raised at during its 2021 IPO.
- How do the revenues of 10x Genomics and Singular Genomics compare?
- 10x Genomics reported $598.7 million in FY2025 revenue and guides for $600 to $625 million in FY2026. Singular Genomics reported only about $1.08 million in revenue for Q4 2023 before going private.
- Could a large company copy 10x Genomics or Singular Genomics?
- A giant copying Singular Genomics is rated likely, while doing the same to 10x Genomics is rated only possible, pointing to a firmer position for 10x Genomics in spatial and single-cell genomics.
Other comparisons with these companies